肺动脉高压(PAH)是一种进行性致死性疾病,其特征是肺血流动力学和血管生长调节受损。这些变化会增加肺血管阻力进而引起肺动脉压,导致右心室衰竭,最终结局是死亡。研究证实内皮素-1升高与PAH的发生发展密切相关,针对内皮素通路的靶向药物不仅能改善PAH患者的症状,而且可以延缓甚至逆转疾病进展,改善患者远期预后。本文回顾该领域的相关文献对内皮素拮抗剂PAH中的作用机制、临床应用及未来前景进行综述。
Pulmonary hypertension (PAH) is a progressive, lethal disease characterized by impaired pulmo-nary hemodynamics and vascular growth regulation. These changes increase pulmonary vascular resistance, which in turn causes pulmonary artery pressure, leading to right ventricular failure, with the end resulting in death. Studies have confirmed that elevated endothelin-1 is closely related to the development of PAH, and targeted drugs targeting the endothelin pathway can not only im-prove symptoms in patients with PAH, but also delay or even reverse disease progression and im-prove long-term prognosis for patients. This paper reviews the literature in this field to review the mechanism of action, clinical application and future prospects of the endothelin antagonist PAH.
Research Advances in ET-1 Antagonistic Drugs in the Treatment of Pulmonary Hypertension
Mengxue Lu1, Zhenzhong Bai2
1Qinghai University, Xining Qinghai
2Plateau Medical Research Center, School of Medicine, Qinghai University, Xining Qinghai
Received: Apr. 27th, 2022; accepted: May 21st, 2022; published: May 31st, 2022
ABSTRACT
Pulmonary hypertension (PAH) is a progressive, lethal disease characterized by impaired pulmonary hemodynamics and vascular growth regulation. These changes increase pulmonary vascular resistance, which in turn causes pulmonary artery pressure, leading to right ventricular failure, with the end resulting in death. Studies have confirmed that elevated endothelin-1 is closely related to the development of PAH, and targeted drugs targeting the endothelin pathway can not only improve symptoms in patients with PAH, but also delay or even reverse disease progression and improve long-term prognosis for patients. This paper reviews the literature in this field to review the mechanism of action, clinical application and future prospects of the endothelin antagonist PAH.
鲁梦雪,白振忠. ET-1拮抗药物治疗肺动脉高压的研究进展Research Advances in ET-1 Antagonistic Drugs in the Treatment of Pulmonary Hy-pertension[J]. 临床医学进展, 2022, 12(05): 4711-4715. https://doi.org/10.12677/ACM.2022.125682
参考文献ReferencesTuder, R.M., Archer, S.L., Dorfmüller, P., Erzurum, S.C., Guignabert, C., Michelakis, E., Rabinovitch, M., Schermuly, R., Stenmark, K.R. and Morrell, N.W. (2013) Relevant Issues in the Pathology and Pathobiology of Pulmonary Hyper-tension. Journal of the American College of Cardiology, 62, D4-D12. <br>https://doi.org/10.1016/j.jacc.2013.10.025Hoeper, M.M., Bogaard, H.J., Condliffe, R., Frantz, R., Khanna, D., Kurzyna, M., Langleben, D., Manes, A., Satoh, T. and Torres, F. (2013) Definitions and Diagnosis of Pulmonary Hypertension. Journal of the American College of Cardiology, 62, D42-D50. <br>https://doi.org/10.1016/j.jacc.2013.10.032Galie, N., Humbert, M., Vachiery, J.L., Gibbs, S., Lang, I., Tor-bicki, A., et al. (2015) 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). European Respiratory Journal, 46, 903-975.
<br>https://doi.org/10.1183/13993003.01032-2015Budhiraja, R., Tuder, R.M. and Hassoun, P.M. (2004) Endo-thelial Dysfunction in Pulmonary Hypertension. Circulation, 109, 159-165. <br>https://doi.org/10.1161/01.CIR.0000102381.57477.50Li, H. and Forstermann, U. (2000) Nitric Oxide in the Pathogenesis of Vascular Disease. The Journal of Pathology, 190, 244-254. <br>https://doi.org/10.1002/(SICI)1096-9896(200002)190:3<244::AID-PATH575>3.0.CO;2-8Li, H., Wallerath, T. and Forstermann, U. (2002) Physiological Mechanisms Regulating the Expression of Endothelial-Type NO Synthase. Nitric Oxide, 7, 132-147. <br>https://doi.org/10.1016/S1089-8603(02)00127-1Davenport, A.P., Hyndman, K.A., Dhaun, N., Southan, C., Kohan, D.E. and Pollock, J.S. (2016) Endothelin. Pharmacological Reviews, 68, 357-418. <br>https://doi.org/10.1124/pr.115.011833Simmet, T., Pritze, S., Thelen, K.I. and Peskar, B.A. (1992) Release of Endothelin in the Oleic Acid-Induced Respiratory Distress Syndrome in Rats. European Journal of Pharmacology, 211, 319-322.
<br>https://doi.org/10.1016/0014-2999(92)90387-JD’Orléans-Juste, P., Davenport, A.P., Godfraind, T., Maguire, J.J., Ohlstein, E.H. and Ruffolo, R.R. (2019) Endothelin Receptors (Version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide to Pharmacology CITE, 1-8. <br>https://doi.org/10.2218/gtopdb/F21/2019.4Enevoldsen, F.C., Sahana, J., Wehland, M., Grimm, D., Infanger, M. and Krüger, M. (2020) Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy. Journal of Clinical Medicine, 9, 824.
<br>https://doi.org/10.3390/jcm9030824Nicholson, S.K., Tucker, G.A. and Brameld, J.M. (2008) Effects of Die-tary Polyphenols on Gene Expression in Human Vascular Endothelial Cells. Proceedings of the Nutrition Society, 67, 42-47.
<br>https://doi.org/10.1017/S0029665108006009Zhao, Y., Vanhoutte, P.M. and Leung, S.W. (2015) Vascular Nitric Oxide: Beyond eNOS. Journal of Pharmacological Sciences, 129, 83-94. <br>https://doi.org/10.1016/j.jphs.2015.09.002Corder, R., Douthwaite, J.A., Lees, D.M., Khan, N.Q., Viseu Dos Santos, A.C., Wood, E.G. and Carrier, M.J. (2001) Endothelin-1 Synthesis Reduced by Red Wine. Nature, 414, 863-864. <br>https://doi.org/10.1038/414863aThompson, A.M., Martin, K.A. and Rzucidlo, E.M. (2014) Resveratrol Induces Vascular Smooth Muscle Cell Differentiation through Stimulation of SirT1 and AMPK. PLoS ONE, 9, e85495.
<br>https://doi.org/10.1371/journal.pone.0085495Wang, D., Uhrin, P., Mocan, A., Waltenberger, B., Breuss, J.M., Tewari, D., Mihaly-Bison, J., Huminiecki, L., Starzynski, R.R., Tzvetkov, N.T., et al. (2018) Vascular Smooth Muscle Cell Proliferation as a Therapeutic Target. Part 1: Molecular Targets and Pathways. Biotechnology Advances, 36, 1586-1607.
<br>https://doi.org/10.1016/j.biotechadv.2018.04.006Rubin, L.J. (2012) Endothelin Receptor Antagonists for the Treatment of Pulmonary Artery Hypertension. Life Sciences, 91, 517-521. <br>https://doi.org/10.1016/j.lfs.2012.07.033Frumkin, L.R. (2012) The Pharmacological Treatment of Pulmonary Arterial Hypertension. Pharmacological Reviews, 64, 583-620. <br>https://doi.org/10.1124/pr.111.005587Dupuis, J., Goresky, C.A. and Fournier, A. (1996) Pulmonary Clearance of Circulating Endothelin-1 in Dogs in Vivo: Exclusive Role of ETB Receptors. Journal of Applied Physiology, 81, 1510-1515.
<br>https://doi.org/10.1152/jappl.1996.81.4.1510Warner, T.D., Mitchell, J.A., de Nucci, G. and Vane, J.R. (1989) Endothelin-1 and Rndothelin-3 Release EDRF from Isolated Perfused Arterial Vessels of the Rat and Rabbit. Journal of Cardiovascular Pharmacology, 13, S85-S88.
<br>https://doi.org/10.1097/00005344-198900135-00021Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K. and Masaki, T. (1988) A Novel Potent Vasoconstrictor Peptide Pro-duced by Vascular Endothelial Cells. Nature, 332, 411-415.
<br>https://doi.org/10.1038/332411a0Stewart, D.J., Levy, R.D., Cernacek, P. and Langleben, D. (1991) Increased Plasma Endothelin-1 in Pulmonary Hypertension: Marker or Mediator of Disease? Annals of Internal Medicine, 114, 464-469.
<br>https://doi.org/10.7326/0003-4819-114-6-464Cody, R.J., Haas, G.J., Binkley, P.F., Capers, Q. and Kelley, R. (1992) Plasma Endothelin Correlates with the Extent of Pulmonary Hypertension in Patients with Chronic Congestive Heart Failure. Circulation, 85, 504-509.
<br>https://doi.org/10.1161/01.CIR.85.2.504Boesen, E.I. (2015) Endothelin Receptors, Renal Effects and Blood Pressure. Current Opinion in Pharmacology, 21, 25-34. <br>https://doi.org/10.1016/j.coph.2014.12.007Wei, A., Gu, Z., Li, J., et al. (2016) Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights from the Meta-Analysis of 4894 Patients from 24 Randomized Double-Blind Placebo-Controlled Clinical Trials. Journal of the American Heart Association, 5, e003896. <br>https://doi.org/10.1161/JAHA.116.003896Paul, G.A., Gibbs, J.S., Boobis, A.R., Abbas, A. and Wilkins, M.R. (2005) Bosentan Decreases the Plasma Concentration of Sildenafil When Coprescribed in Pulmonary Hypertension. British Journal of Clinical Pharmacology, 60, 107- 112. <br>https://doi.org/10.1111/j.1365-2125.2005.02383.xMcLaughlin, V., Channick, R.N., Ghofrani, H.A., et al. (2015) Bosentan Added to Sildenafil Therapy in Patients with Pulmonary Arterial Hypertension. European Respiratory Journal, 46, 405-413.
<br>https://doi.org/10.1183/13993003.02044-2014